Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danazol as first-line treatment for lower-risk MDS/CMML and ICUS
KCT0005060Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of danazol in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), idiopathic cytopenia of uncertain significance (ICUS), sponsored by Asan Medical Center. Started Apr 2020; status: recruiting.
02
Drugs
danazol
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)idiopathic cytopenia of uncertain significance (ICUS)
Beyond the preview
Go deeper on KCT0005060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005060.